Literature DB >> 11050055

Effects of short-term leptin exposure on triglyceride deposition in rat liver.

M Roden1, C Anderwald, C Fürnsinn, W Waldhäusl, A Lohninger.   

Abstract

Leptin has recently been suggested to play a role in the pathogenesis of hepatic steatosis. Consequently, this study was designed to examine the direct effects of portal leptin on the intrahepatic lipid contents in the postabsorptive state. Rat livers (n = 6 per group) were perfused in a recirculating system and portally infused with leptin (0.5 nmol/L, 5 nmol/L, and 25 nmol/L), insulin (10 nmol/L), leptin (5 nmol/L) plus insulin (10 nmol/L), glucagon (1 nmol/L), or vehicle (control). Intrahepatic contents of triglycerides, free cholesterol, cholesteryl esters, and free fatty acids were determined from the lipid extract of frozen livers by capillary gas chromatography. Short-term leptin infusion increased total triglycerides in a concentration-dependent (0.5 nmol/L: 2.8 +/- 0.4 mg/g, 5 nmol/L: 7.0 +/- 0.5 mg/g, 25 nmol/L: 8.3 +/- 1.0 mg/g) and time-dependent manner. Total triglycerides also rose during exposure to insulin plus leptin (7.2 +/- 0.6 mg/g) but fell during glucagon infusion (2.6 +/- 0.2 mg/g; control: 4.3 +/- 0.3 mg/g; P <.05). Leptin, insulin, and glucagon increased intrahepatic free cholesterol (P <.05). Free fatty acids were also higher during leptin exposure (0.5 nmol/L: 1.28 +/- 0.08 mg/g, 5 nmol/L: 0.47 +/- 0.01 mg/g, 25 nmol/L: 0.48 +/- 0.04 mg/g, control: 0.38 +/- 0.03 mg/g; P <.05). In conclusion, hyperleptinemia increases hepatic triglyceride content and may therefore contribute to hepatic steatosis in hyperleptinemic obese patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11050055     DOI: 10.1053/jhep.2000.18712

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  7 in total

1.  Hepatic glucose production and insulin resistance.

Authors:  Michael Roden
Journal:  Wien Med Wochenschr       Date:  2008

Review 2.  Effect of CPAP therapy on liver disease in patients with OSA: a review.

Authors:  Xin Liu; Yuyang Miao; Fan Wu; Tingting Du; Qiang Zhang
Journal:  Sleep Breath       Date:  2018-01-11       Impact factor: 2.816

Review 3.  Leptin in the field of hepatic fibrosis: a pivotal or an incidental player?

Authors:  Sotirios K Bethanis; Stamatios E Theocharis
Journal:  Dig Dis Sci       Date:  2006-10       Impact factor: 3.199

4.  Adipose tissue dysfunction signals progression of hepatic steatosis towards nonalcoholic steatohepatitis in C57BL/6 mice.

Authors:  Caroline Duval; Uwe Thissen; Shohreh Keshtkar; Bertrand Accart; Rinke Stienstra; Mark V Boekschoten; Tania Roskams; Sander Kersten; Michael Müller
Journal:  Diabetes       Date:  2010-09-21       Impact factor: 9.461

Review 5.  [Future targets in the treatment of type 2 diabetes].

Authors:  Harald Stingl; Michael Roden
Journal:  Wien Klin Wochenschr       Date:  2004-04-30       Impact factor: 1.704

6.  Brain leptin reduces liver lipids by increasing hepatic triglyceride secretion and lowering lipogenesis.

Authors:  Martina Theresa Hackl; Clemens Fürnsinn; Christina Maria Schuh; Martin Krssak; Fabrizia Carli; Sara Guerra; Angelika Freudenthaler; Sabina Baumgartner-Parzer; Thomas H Helbich; Anton Luger; Maximilian Zeyda; Amalia Gastaldelli; Christoph Buettner; Thomas Scherer
Journal:  Nat Commun       Date:  2019-06-20       Impact factor: 14.919

7.  Serum leptin levels correlate with body mass index but not with histologic disease severity in Indian patients with non-alcoholic steatohepatitis: a pilot study.

Authors:  Deepak Kumar Singh; Puja Sakhuja; Archana Rastogi; Anubha Singh; Ranjana Gondal; Shiv Kumar Sarin
Journal:  Indian J Med Res       Date:  2013-05       Impact factor: 2.375

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.